Related by context. All words. (Click for frequent words.) 78 randomly assigned 78 randomized double 77 randomized controlled 77 randomized placebo controlled 77 randomized clinical 77 placebo controlled 76 randomized #:# 75 prospective randomized 74 multicenter randomized 74 multicenter 74 blind randomized 73 double blind placebo 73 randomized controlled trial 72 nonrandomized 71 multicentre 71 blind randomized placebo 71 n = 70 randomized multicenter 69 multicenter randomized double 68 controlled multicenter 68 double blinded randomized 67 Phase III randomized 67 prospective randomized controlled 67 randomization 67 multicentre randomized 67 randomized blinded 67 label multicenter 67 prospective cohort 67 prospective multicenter 67 randomized #:#:# 66 blinded randomized 66 blind placebo controlled 66 double blinded placebo 66 multicenter prospective 66 blinded placebo controlled 66 dose dose escalation 66 blind placebo 66 randomized Phase III 66 multicenter study 66 placebo controlled randomized 66 placebo 65 dose escalation 65 active comparator 65 Randomized 65 randomized trials 65 multicentre randomized double 65 multicenter randomized controlled 65 trials RCTs 65 randomized controlled trials 65 dose escalation study 64 prospective observational 64 randomisation 64 prospective randomized placebo 64 placebo controlled clinical 63 prospective randomized multicenter 63 randomized controlled clinical 63 unblinded 63 multicenter randomized placebo controlled 63 observational study 63 multicenter clinical 63 placebo controlled Phase 62 #mg QD [002] 62 randomized crossover 62 ascending dose 62 dose escalation trial 62 randomized multicentre 62 label dose escalation 62 prospectively randomized 62 randomized clinical trials 61 pegylated interferon alfa 2b 61 evaluable 61 mg QD 61 TMC# C# 61 Phase 2b study 61 blind randomized controlled 61 evaluable patients 61 mg BID 61 label dose titration 61 multicenter Phase II 61 FOLFOX 60 monotherapy 60 randomize 60 multicenter multinational 60 placebo controlled Phase III 60 prospective multicenter randomized 60 #mg/day [001] 60 ascending doses 60 mcg kg 60 #:# randomization 60 randomized multicenter trial 60 dosing cohorts 59 adalimumab 59 viral kinetic 59 non inferiority 59 subanalysis 59 multicenter Phase 59 dose cohorts 59 substudy 59 dose titration 59 mg dose 59 clinical trial 59 Phase 1b clinical 59 dose regimens 59 prospectively defined 59 multicentre study 59 neoadjuvant 59 treatment naive genotype 59 Phase IIIb 59 phase IIa 59 antiretroviral naive 59 peginterferon alfa 2b 59 BRIM2 58 nab paclitaxel 58 randomized Phase 58 LEXIVA r 58 phase IIb clinical 58 multicenter placebo controlled 58 blind multicenter 58 placebo controlled studies 58 RRMS patients 58 EURIDIS 58 randomized blinded placebo 58 placebo controlled dose escalation 58 mg d 58 multicenter Phase III 58 Randomised 58 Phase 1b 58 docetaxel 58 blinded randomized placebo controlled 58 dose escalation Phase 58 prospective nonrandomized 58 Randomized controlled 58 single ascending dose 58 blinded randomized controlled 58 prespecified 58 HCV SPRINT 58 weekly subcutaneous injections 58 LPV r 58 treatment naïve genotype 58 #mg QD [001] 58 darunavir ritonavir 58 stage IIIB 58 retrospective cohort study 58 RE LY ® 58 randomized controlled clinical trials 58 insulin detemir 58 symptomatic BPH 57 placebo controlled trials 57 pegylated interferon 57 dosage regimens 57 mg administered orally 57 vicriviroc 57 NSTE ACS 57 blinded placebo 57 pharmacokinetics PK 57 masked placebo controlled 57 EVEREST II 57 Phase Ib clinical 57 observational studies 57 virologic failure 57 DCCT 57 eptifibatide 57 Edge STudy 57 dose escalation clinical 57 mg/m2 dose 57 preoperative chemotherapy 57 mcg albinterferon alfa 2b 57 randomized placebo 57 AIR CF1 57 Phase 2b clinical 57 phase Ib 57 APTIVUS r 57 dose escalation phase 57 vinorelbine 57 randomized Phase IIb 57 label multicenter randomized 57 antiretroviral naïve 57 controlled dose escalation 57 phase IIIb 57 safety tolerability pharmacokinetics 57 Phase IIb 56 placebo controlled clinical trials 56 lopinavir r 56 mg kg dose 56 irbesartan 56 PRECiSE 56 normotensive 56 paclitaxel eluting stents 56 sirolimus eluting stent 56 PREZISTA r 56 HCV infected 56 DAPT 56 Phase #/#a 56 HCV RESPOND 2 56 noninferiority 56 HF ACTION 56 NO# [002] 56 phase IIb 56 plus ribavirin 56 Phase III randomized controlled 56 multicenter phase 56 infliximab 56 retrospective cohort 56 sunitinib 56 blind multicentre 56 TDF FTC 56 gemcitabine 56 #mg/m# [002] 56 mcg 56 oral rivaroxaban 56 sirolimus eluting stents 56 Phase IIb trial 56 prospective multicentre 56 AIR CF3 56 multiple ascending dose 56 postmenopausal women 56 dosing cohort 56 Phase 2a trial 56 BR.# 56 label multicenter Phase 56 chemoradiotherapy 56 ONTARGET 56 Phase IIIb study 56 tiotropium 56 4mg/kg 56 landmark ATHENA 56 #mg BID [001] 56 mg kg 55 cohort 55 administered subcutaneously 55 TAXUS ATLAS 55 BCIRG 55 timepoint 55 primary endpoint 55 atazanavir ritonavir 55 RE LY 55 MADIT II 55 bevacizumab 55 Multicenter 55 Phase 2b 55 Thrombolysis 55 5-FU/LV 55 liver transplant recipients 55 phase IIa clinical 55 peginterferon alfa 2a 55 ACTIVE W 55 Phase Ib 55 relapsed MM 55 sirolimus eluting 55 secondary endpoint 55 tolerability 55 efavirenz EFV 55 HbA1c levels 55 desvenlafaxine succinate 55 saline placebo 55 low dose cytarabine 55 subgroup analyzes 55 antihypertensive therapy 55 telaprevir dosing 55 evaluable subjects 55 methotrexate monotherapy 55 Acute Coronary Syndromes ACS 55 Taxotere ® 55 Carotid Revascularization Endarterectomy vs. 55 UKPDS 55 recurrent glioblastoma multiforme 55 RCTs 55 dacarbazine 55 stage IIIb IV 55 NCT# ClinicalTrials.gov 55 chlorambucil 55 everolimus eluting stents 55 comparing XIENCE V 55 Prostate Lung Colorectal 55 ug dose 55 Phase 1a 55 PREZISTA ritonavir 55 comparator arm 55 ABSORB trial 55 Phase 2b trial 55 Phase Ia 55 histologically confirmed 55 multicentre prospective 55 bosentan 55 unfractionated heparin 55 metastatic HRPC 55 BRIM3 54 pharmacodynamics 54 ongoing Phase 1b 54 post hoc 54 Baseline characteristics 54 COMFORT II 54 XELOX 54 undetectable HBV DNA 54 mg RDEA# 54 Randomized Evaluation 54 safety tolerability 54 dosing 54 retrospective observational study 54 pegylated liposomal doxorubicin 54 meta analysis 54 Myocardial Infarction Study 54 mitoxantrone 54 FOLFIRI 54 patients evaluable 54 NSABP B 54 peginterferon 54 demonstrated statistically significant 54 3TC lamivudine Epivir 54 CLL8 54 neoadjuvant chemotherapy 54 ENDEAVOR IV 54 dose cohort 54 SPIRIT III 54 randomized Phase 2b 54 mg/m2 54 REALITY Trial 54 BEACOPP 54 CLARITY study 54 Sorafenib HCC Assessment 54 TAXUS V 54 ritonavir boosted 54 #mg BID [003] 54 abacavir lamivudine 54 tenofovir emtricitabine 54 8mg/kg 54 carboplatin paclitaxel 54 observer blinded randomized 54 Phase Ib II 54 viral kinetics 54 statistically significant 54 nulliparous women 54 citalopram 54 multicenter randomized clinical 54 chemoradiation 54 μg dose 54 metastatic renal cell carcinoma 54 mcg BID 54 Phase IIa 54 Phase 2a clinical 54 lacosamide 54 Secondary endpoints 54 adjuvant tamoxifen 54 intravenous dose 54 Phase III clinical 54 AIR CF2 54 Traficet EN 54 Phase 2b randomized 54 composite endpoint 54 Raloxifene Evaluation MORE 54 patients undergoing percutaneous 54 unstable angina UA 54 Efficacy 54 Phase IIb clinical 54 statistically significant improvement 54 median PFS 54 subcutaneously administered 54 FOLPI 54 #mg/kg [002] 54 APTIVUS 54 Primary endpoints 54 factorial design 54 unfractionated heparin UFH 54 secondary efficacy endpoints 54 statistically significant differences 53 SWOG 53 ATACAND 53 prospectively stratified 53 daily subcutaneous injections 53 ROCKET AF 53 pharmacokinetic PK 53 hemodialysis patients 53 Polyp Prevention Trial 53 undergoing coronary angiography 53 PARTNER Trial 53 longitudinal cohort study 53 null responder HCV 53 peg IFN 53 pharmacokinetic 53 NEVO RES 53 randomized controlled multicenter 53 Phase III placebo controlled 53 intravenous dosing 53 #mg/m# [001] 53 FOLFOX4 53 dabigatran etexilate 53 recurrent GBM 53 undergone radical prostatectomy 53 postintervention 53 XIENCE V demonstrated 53 recurrent malignant glioma 53 placebo controlled multicenter 53 primary efficacy endpoint 53 mcg dose 53 CAMMS# 53 CIMZIA TM certolizumab pegol 53 prospectively 53 placebo dexamethasone 53 ABC/3TC 53 cluster randomized controlled 53 mg ustekinumab 53 Phase III VISTA 53 ACTEMRA TM 53 lipid lowering therapy 53 observational cohort 53 daily Infergen 53 timepoints 53 mg qd 53 plus dexamethasone 53 HCV genotype 1 53 pharmacokinetics 53 GATTEX therapy 53 carboplatin 53 multicentre randomized controlled 53 NICE SUGAR 53 PRoFESS 53 rosuvastatin 53 Phase III randomized placebo 53 LUX Lung 53 Phase IIa trial 53 Folfox 53 CYPHER R Stent 53 CHOP chemotherapy 53 prospective observational cohort 53 DMARD 53 VADT 53 ticagrelor 53 q#h 53 Intervention Trial 53 RSD# oral 53 bendamustine 53 evaluating REVLIMID 53 premenopausal 53 mg TID 53 IV NSCLC 53 events AEs 53 randomized controlled Phase 53 Phase IIIb clinical 53 pivotal Phase 53 histologically proven 53 bolus injection 53 sequential dose escalation 53 ADVANCE PD 53 observational cohort study 53 mcg doses 53 WHIMS 53 cisplatin vinorelbine 53 Phase III 53 secondary endpoints 53 SORT OUT III 53 NATRECOR ® 53 Free Survival PFS 53 OADs 53 REYATAZ r 53 mcg QD 53 ECASS 53 etanercept 53 relapsed myeloma 53 prospective multicenter study 52 dose regimen 52 Endovascular Valve Edge 52 Phase III pivotal 52 phase IIb study 52 ARIXTRA 52 AVOREN 52 ribavirin RBV 52 metastatic RCC 52 unresectable stage 52 #mg dosing 52 relapsed refractory ALL 52 mg subcutaneously 52 adjuvant chemotherapy 52 tipranavir ritonavir 52 nondiabetic patients 52 intravitreal injection 52 glatiramer acetate 52 APPRAISE 52 concomitant medications 52 rt PA 52 demonstrated clinically meaningful 52 patients undergoing CABG 52 MIST II 52 oral sapacitabine 52 dosing regimens 52 unblinding 52 bolus dose 52 TG MV 52 ASCEND HF 52 e HEALING 52 underwent CABG 52 docetaxel prednisone 52 TRITON TIMI 52 sunitinib malate 52 Placebo controlled 52 Amrubicin 52 diagnosed GBM 52 pioglitazone 52 CALGB 52 BOLDER II 52 resectable 52 mg 52 HCV genotype 52 multinational multicenter randomized 52 HPTN 52 intermittent dosing 52 CATIE AD 52 μg 52 rapid virologic response 52 ExTRACT TIMI 52 Clinical Antipsychotic Trials 52 FAME Study 52 EINSTEIN DVT 52 Betaferon ® 52 dacarbazine chemotherapy 52 melphalan prednisone 52 Peg IFN 52 goserelin 52 oral deforolimus 52 lamivudine monotherapy 52 NLX P# 52 RLAI 52 NOXAFIL Oral Suspension 52 crizotinib PF # 52 Phase IIB 52 Phase 1b trial 52 pharmacodynamics PD 52 nonmetastatic prostate cancer 52 Initiated Phase 52 conjugated equine estrogen 52 everolimus eluting stent 52 paclitaxel poliglumex 52 #mg BID [002] 52 paclitaxel carboplatin 52 HBeAg positive 52 certolizumab 52 subcutaneous injections 52 IFN alfa 52 postmenopausal osteoporotic women 52 olmesartan 52 pivotal Phase III 52 valsartan 52 clopidogrel 52 LCP AtorFen 52 tirofiban 52 Pivotal Trial 52 BARI 2D 52 Radiation Therapy Oncology 52 Kaplan Meier analysis 52 CANCIDAS 52 estramustine 52 CR nPR 52 subcutaneous doses 52 achieved statistical significance 52 inactive placebo 52 TMC# r 52 EchoCRT 52 doxorubicin docetaxel 52 rFVIIa 52 plus gemcitabine 52 pemetrexed 52 low dose dexamethasone 52 neoadjuvant treatment 52 mg Lucentis 52 ascending dose study 52 Pegasys plus Copegus 52 prospective longitudinal 52 CIMZIA TM 52 SIMPADICO 52 noninferior 52 cystectomy 52 free survival PFS 52 placebo intravenously 52 IMPROVE HF 52 octreotide LAR 52 HYVET 52 lamivudine 52 mRCC 52 bronchial thermoplasty 52 KRAS mutations occur 52 virological failure 52 statin therapy 52 relapsing multiple sclerosis 52 Val HeFT 52 chemoradiation therapy 52 temsirolimus 52 fluorouracil 52 IIa trial 52 radical cystectomy 52 multicenter trials 52 concurrent chemoradiation 52 intradermal injections 52 lopinavir ritonavir 52 dosed 52 mg doses 52 plus methotrexate 52 phase IIb trial 52 pegylated interferon alfa 2a 52 phase 2a 52 Monotherapy 52 relapsed refractory multiple myeloma 52 DAS# scores 52 de novo kidney transplant 52 p = 52 fibrinolytic therapy 52 DLTs 51 nadroparin 51 virologic 51 Stenting Trial CREST 51 ABSORB clinical 51 TRANSFORMS 51 Researchers randomly assigned 51 coronary revascularization 51 p = #.# [002] 51 IV bolus 51 tolvaptan 51 chemotherapy docetaxel 51 ritonavir boosted lopinavir 51 genotypic resistance 51 colesevelam HCl 51 DMARD therapy 51 metastatic hormone refractory 51 experienced virologic failure 51 paricalcitol 51 decitabine 51 sorafenib Nexavar 51 fondaparinux 51 primary hypercholesterolemia 51 underwent percutaneous coronary 51 ALLHAT 51 angiographic 51 cetuximab 51 capecitabine 51 ritonavir boosted atazanavir 51 TEAEs 51 pharmacodynamic PD 51 adjunctive placebo 51 Phase #b/#a 51 underwent liver transplantation 51 hypogonadal men 51 confirmatory clinical 51 REVIVE Diabetes 51 nonresponders 51 TMC# [001] 51 Flu Cy 51 dietary questionnaires 51 protease inhibitor PI 51 acute STEMI 51 AZILECT R 51 telaprevir dosed 51 EORTC 51 retrospectively analyzed 51 docetaxel chemotherapy 51 pegylated interferon alpha 51 lispro 51 squamous histology 51 dose cytarabine 51 oxycodone CR 51 Randomized Phase 51 NATRECOR R 51 adjuvant therapy 51 MGd 51 Taxus Stent 51 ACTEMRA 51 AIM HIGH 51 bivalirudin 51 metastatic CRPC 51 refractory CLL 51 primary percutaneous coronary 51 SCIg 51 Phase III multicenter 51 APEX PD 51 zonisamide SR 51 stable angina 51 LibiGel Phase III 51 COPAXONE R 51 DSMB 51 HER2 positive metastatic breast 51 virological response 51 telmisartan 51 lymphadenectomy 51 relapsed APL 51 acute coronary syndromes ACS 51 OLYMPIA registry 51 venlafaxine XR 51 vandetanib 51 HBeAg negative patients 51 diagnosed multiple myeloma 51 Doxil ® 51 beta blocker therapy 51 tapentadol ER 51 underwent resection 51 Median survival 51 primary endpoints 51 posaconazole 51 CARE HF 51 relapsing remitting MS 51 oral ibandronate 51 BENICAR HCT 51 virologic response 51 ragweed allergic 51 superficial bladder cancer 51 heavily pretreated 51 TAXOTERE R 51 non valvular atrial 51 warfarin therapy 51 plus prednisone 51 PEG Intron ® 51 androgen deprivation 51 ancrod 51 copies mL 51 Endeavor Resolute DES 51 NCCTG 51 androgen suppression 51 CYPHER R stent 51 MIRCERA 51 heavily pretreated patients 51 pimecrolimus cream 51 achieved ACR# 51 sustained virological response 51 Q2W 51 postmenopausal 51 azacitidine 51 intravenous doses 51 CUSTOM III 51 multicenter randomized Phase 51 controlled multicenter Phase 51 TAXUS Liberte Stent 51 daunorubicin 51 Communities ARIC study 51 adjuvant radiotherapy 51 ziprasidone 51 dirucotide MBP# 51 TAXUS stent 51 CYPHER ® Stent 51 RG# ITMN 51 Phase 2a 51 Percutaneous Coronary Intervention 51 salmeterol fluticasone 51 registrational Phase 51 dose placebo controlled 51 STEMI patients 51 naïve HCV 51 dose pharmacokinetic 51 risperidone Risperdal 51 evaluating tivozanib 51 lenalidomide dexamethasone 51 nucleoside naive patients 51 continuous intravenous infusion 51 paroxysmal AF 51 lopinavir r arm 51 SYNTAX trial 51 CUSTOM II 51 safety tolerability pharmacokinetic 51 cilostazol 51 #mg dose [003] 51 transfemoral 51 biochemical recurrence 51 TACE 51 analgesic efficacy 51 letrozole 51 pomalidomide 51 PEG IFN 51 NRTI 50 pregabalin 50 Multiple Ascending Dose 50 placebo PBO 50 HOPE TOO 50 male Wistar rats 50 cetrorelix 50 pazopanib 50 d4T 50 multidose 50 VELCADE melphalan 50 teriflunomide 50 EDEMA3 50 BoNTA 50 fallopian tube cancers 50 abciximab 50 fallopian tube carcinoma 50 dual antiplatelet therapy 50 elective PCI 50 Pegasys ® 50 RoACTEMRA 50 SPIRIT IV 50 TAXUS VI 50 tocilizumab 50 atazanavir 50 dosing schedules 50 μg kg 50 interferon alfa 2b 50 aromatase inhibitor therapy 50 diuretic chlorthalidone 50 bevacizumab Avastin 50 tumor histology 50 Multi Ethnic Study 50 TYKERB 50 SPIRIT FIRST 50 EMPHASIS HF 50 Prospective Randomized Trial 50 tamoxifen therapy 50 GAMMAGARD 50 Raptiva r 50 nitazoxanide 50 NEVO 50 nephrectomy 50 Cohort 50 ibandronate 50 genotyped 50 Taxotere R 50 longitudinal study 50 meta analyzes 50 AVADO 50 partial remissions 50 adefovir 50 mCRC patients 50 azathioprine 50 VIRAMUNE XR 50 eribulin mesylate 50 p = #.# [004] 50 CYPHER Stent 50 biliary tract cancer 50 PICSO ® 50 #mg ATC 50 Allovectin 7 ® 50 clevidipine 50 abatacept 50 mg m 50 confirmatory Phase III 50 rilpivirine 50 nonmetastatic 50 galiximab 50 lubiprostone 50 EFAPROXYN 50 nondiabetic 50 GOUT 50 clinical pharmacology studies 50 sitagliptin 50 evaluating Vectibix 50 intra articular injection 50 interferon alfa 2a 50 fosbretabulin 50 SCH # 50 QD dosing 50 fistulizing Crohn disease 50 RECORD1 50 tamsulosin 50 randomized controlled trials RCTs 50 eosinophilic asthma 50 RTOG 50 sorafenib Nexavar ® 50 overnight polysomnography 50 XIENCE V PROMUS Stent 50 visilizumab 50 mg simvastatin 50 IMPROVE IT 50 GetGoal Phase III 50 titrated 50 pharmacokinetic pharmacodynamic 50 multicentric 50 enoxaparin 50 REVLIMID lenalidomide 50 progression TTP 50 HCV RNA 50 CHAMPION PCI 50 tolerated dose MTD 50 TAXUS 50 divalproex sodium 50 efficacy endpoints 50 darunavir r 50 pravastatin 50 Dose escalation 50 QTcF 50 stavudine d4T 50 RG# [001] 50 subcutaneous dose 50 endoscopic remission 50 tipranavir r 50 standard chemotherapy regimen 50 afatinib 50 STRIDE PD 50 #mg/day [002] 50 Phase 2b kidney transplant 50 Prostate Cancer Prevention 50 VICTOR E1 50 Subgroup analyzes 50 AIR2 Trial 50 randomizing 50 dyskinesia PD LID 50 GnRH agonist 50 ABVD 50 Neovascular AMD 50 flutamide 50 certolizumab pegol 50 chemotherapy regimen 50 FOSRENOL R 50 Acute Ischemic Stroke 50 Study ADX# 50 retinal thickness 50 COU AA 50 CML CP 50 ACCOMPLISH 50 XIENCE V Stent System 50 pegaptanib 50 mg Pycnogenol 50 intravenous bolus 50 MERLIN TIMI 50 sorafenib 50 candesartan cilexetil 50 creatinine clearance 50 genotype 1a 50 ezetimibe simvastatin 50 boosted protease inhibitor 50 anti arrhythmic drug 50 cells mcL 50 mg Proellex 50 CsA 50 R# #mg BID 50 oral COTI 50 platinum refractory 50 liver metastases 50 MIRAPEX 50 serum phosphorus 50 FDG PET scans 50 mCi kg 50 Navelbine 50 prospectively enrolled 50 Subgroup analysis 50 ceftazidime 50 HGS ETR1 50 unresectable 50 Capesaris 50 mycophenolate mofetil 50 mg FV 50 temozolomide 50 oral FTY# 50 riociguat 50 low dose Iluvien 50 secondary efficacy endpoint 50 solifenacin 50 montelukast 50 tenecteplase 50 PREZISTA rtv 50 preintervention 50 XGEVA 50 Screening Trial 50 elagolix 50 QTc 50 Pharmacokinetics PK 50 undetectable HCV RNA 50 liposomal doxorubicin 50 inhaled tobramycin 50 Randomized Study 50 sustained virologic response 50 relapsed AML 50 pyridostigmine 50 NPH insulin 50 efficacy 50 NMIBC 50 RECIST criteria 50 TAXUS IV 50 glufosfamide 50 Randomized Double Blind Placebo 50 MADIT CRT trial 50 CALGB # [002] 49 refractory NSCLC 49 mg q#h 49 REYATAZ r arm 49 Xelox 49 rituximab 49 lamotrigine 49 ischemic cardiomyopathy 49 Fludara 49 pramlintide 49 lumbar spine BMD 49 subcutaneous SC 49 REVIVE 49 HORIZONS AMI trial 49 peginterferon alfa 2a #KD 49 Phase Ib study 49 avosentan 49 EVIZON 49 liver resection 49 rimonabant #mg 49 glucose intolerant 49 ipsilateral stroke 49 REBETOL 49 mg/m2 cohort 49 paclitaxel eluting stent 49 hyperlipidemic 49 Elitek 49 pharmacokinetic PK study 49 FOLFIRI alone 49 OPT CHF 49 randomized multicenter Phase III 49 epirubicin cyclophosphamide 49 EOquin TM 49 GEM OS1 49 insulin glargine 49 CABG